Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,368 | 155 | 99.6% |
| Consulting Fee | $18.58 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $799.60 | 16 | $0 (2023) |
| Gilead Sciences, Inc. | $603.73 | 10 | $0 (2023) |
| Intercept Pharmaceuticals, Inc. | $534.66 | 9 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $418.58 | 18 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $342.10 | 32 | $0 (2023) |
| Allergan Inc. | $259.52 | 23 | $0 (2018) |
| PFIZER INC. | $142.61 | 2 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $136.31 | 2 | $0 (2024) |
| Janssen Biotech, Inc. | $125.64 | 7 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $151.16 | 3 | Phathom Pharmaceuticals, Inc. ($136.31) |
| 2023 | $446.07 | 9 | Gilead Sciences, Inc. ($125.00) |
| 2022 | $358.45 | 4 | PFIZER INC. ($127.76) |
| 2021 | $534.43 | 18 | AbbVie Inc. ($227.93) |
| 2020 | $343.49 | 13 | Intercept Pharmaceuticals, Inc. ($133.65) |
| 2019 | $1,013 | 32 | AbbVie, Inc. ($226.06) |
| 2018 | $756.77 | 34 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($206.32) |
| 2017 | $783.46 | 43 | Allergan Inc. ($224.48) |
All Payment Transactions
156 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $11.31 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/25/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/20/2023 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 06/07/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $120.84 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/30/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/04/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HCV | ||||||
| 04/28/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $72.29 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/28/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: INTERNAL MEDICINE | ||||||
| 03/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/21/2023 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $36.32 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/01/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $84.00 | General |
| Category: VIROLOGY | ||||||
| 11/09/2022 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Neuroscience | ||||||
| 10/22/2022 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $127.76 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/30/2022 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/02/2021 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $94.50 | General |
| Category: HCV | ||||||
| 11/10/2021 | Takeda Pharmaceuticals U.S.A., Inc. | MOTEGRITY (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: INTERNAL MEDICINE | ||||||
| 08/05/2021 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $103.11 | General |
| Category: HEPATOLOGY GASTROENTEROLOGY | ||||||
| 07/20/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: VIROLOGY | ||||||
| 07/08/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $29.58 | General |
| Category: VIROLOGY | ||||||
| 06/22/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: VIROLOGY | ||||||
| 06/03/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $102.00 | General |
| Category: VIROLOGY | ||||||
| 06/01/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: Gastroenterology | ||||||
| 05/21/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.64 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,800 | 1,914 | $1.2M | $190,372 |
| 2022 | 12 | 1,908 | 2,046 | $1.3M | $204,233 |
| 2021 | 14 | 2,035 | 2,215 | $1.4M | $226,271 |
| 2020 | 13 | 2,147 | 2,354 | $1.3M | $223,692 |
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 259 | 260 | $331,760 | $38,276 | 11.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 169 | 173 | $288,218 | $34,776 | 12.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 275 | 314 | $68,100 | $28,400 | 41.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 334 | 334 | $75,325 | $26,241 | 34.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 315 | 338 | $52,635 | $23,616 | 44.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 117 | 121 | $145,684 | $9,802 | 6.7% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 151 | 155 | $150,970 | $9,514 | 6.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 64 | 64 | $82,304 | $8,644 | 10.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 73 | $12,775 | $4,661 | 36.5% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 60 | 63 | $15,750 | $4,092 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $6,460 | $2,349 | 36.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 262 | 265 | $338,140 | $38,497 | 11.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 164 | 170 | $283,220 | $34,669 | 12.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 297 | 354 | $77,880 | $33,067 | 42.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 348 | 374 | $57,970 | $26,082 | 45.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 333 | 333 | $74,925 | $23,713 | 31.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 193 | 195 | $189,930 | $11,620 | 6.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 118 | 125 | $150,500 | $9,715 | 6.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 65 | 65 | $83,590 | $8,660 | 10.4% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 11 | 11 | $26,895 | $6,903 | 25.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 38 | 74 | $12,950 | $4,151 | 32.1% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 53 | 54 | $13,500 | $4,079 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 26 | 26 | $8,840 | $3,077 | 34.8% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 256 | 256 | $326,656 | $38,884 | 11.9% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 175 | 182 | $303,212 | $38,193 | 12.6% |
About Dr. Bradley Mackler, M.D
Dr. Bradley Mackler, M.D is a Gastroenterology healthcare provider based in Seaford, Delaware. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356430854.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bradley Mackler, M.D has received a total of $4,386 in payments from pharmaceutical and medical device companies, with $151.16 received in 2024. These payments were reported across 156 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($4,368).
As a Medicare-enrolled provider, Mackler has provided services to 7,890 Medicare beneficiaries, totaling 8,529 services with total Medicare billing of $844,567. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Seaford, DE
- Active Since 10/12/2006
- Last Updated 03/14/2012
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1356430854
Products in Payments
- Epclusa (Drug) $444.50
- XIFAXAN (Drug) $439.64
- Mavyret (Drug) $356.90
- MAVYRET (Drug) $324.02
- OCALIVA (Drug) $320.10
- Amitiza (Drug) $226.35
- OCA (Drug) $214.56
- VIBERZI (Drug) $206.00
- XELJANZ (Drug) $142.61
- VOQUEZNA (Drug) $136.31
- ZEPOSIA (Drug) $125.00
- Lenvima (Drug) $123.79
- REBYOTA (Biological) $120.84
- Vemlidy (Drug) $114.48
- STELARA (Biological) $105.41
- ENTYVIO (Biological) $87.98
- Doptelet (Drug) $84.77
- LINZESS (Drug) $84.67
- DUPIXENT (Biological) $72.29
- Viekira (Drug) $60.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Seaford
Dr. Ismet Lukolic, M.d, M.D
Gastroenterology — Payments: $6,753
Dr. Ronald Concha Parra, Md, MD
Gastroenterology — Payments: $3,019
Corina Serer, Md, MD
Gastroenterology — Payments: $2,293
Theodore Perlman, Md, MD
Gastroenterology — Payments: $1,930
Adam Beckerman, Md, MD
Gastroenterology — Payments: $1,364
Lester Goldblum, Do, DO
Gastroenterology — Payments: $75.50